As a physician, few things are harder than seeing a promising treatment emerge while knowing that patients may not be able to access it.
I treat patients with AL amyloidosis, a rare, life-threatening disease in which abnormal proteins build up in vital organs, including the heart and kidneys, potentially causing organ failure. Although many patients respond to initial treatment, others relapse or don’t respond at all or enough. For these patients, there are no FDA-approved therapies specifically indicated after treatment failure.
Physicians are left relying on off-label treatments, while the disease continues to cause irreversible damage. I’ve witnessed firsthand patients in this setting deteriorate.
Fortunately, promising new therapies are in development, but bringing these treatments to patients requires a regulatory system that recognizes the urgency of rare diseases and the challenges of developing therapies for small, medically fragile populations.
With Congress back in session this week, lawmakers have an opportunity to move forward with Dr. Heidi Overton’s pending confirmation to lead the FDA at a crucial moment for rare disease. During the National Organization for Rare Disorders’ breakthrough summit, Acting FDA Commissioner Kyle Diamantas called the agency’s new Rare Disease Framework Initiative a top priority.
If confirmed, Overton has an opportunity to turn that commitment into clear, predictable approval pathways that account for the realities of rare disease drug development. Patients whose conditions lack any effective therapies depend on those decisions, which could mean the difference between life and death.
Randomized controlled trials are the gold-standard and remain essential to evaluating new treatments. But for rare diseases like AL amyloidosis, patient populations are small and heterogenous. In many patients, the disease progresses rapidly. Recruiting enough participants can take years, and many patients simply don’t have that kind of time.
There are also ethical concerns. When patients have exhausted existing treatment options, is it reasonable to assign some to a less efficacious therapy when more promising alternatives are available?
The FDA has historically recognized these challenges by allowing alternative approaches, including single-arm trials in which every participant receives the investigational therapy. However, recent conflicting signals from the agency have raised questions about when these studies can support drug approvals.
Last year, comments attributed to officials at the FDA’s Center for Biologics Evaluation and Research suggested that single-arm data may no longer be sufficient for rare disease approvals. Although agency leadership later clarified that those comments did not reflect official FDA policy, uncertainty remains about what evidence developers will need to bring new treatments to patients. And this isn’t just a bureaucratic issue. It has real consequences for patients facing life-threatening diseases.
Alongside treating patients with AL amyloidosis, I serve as a clinical investigator on clinical trials evaluating novel investigational drugs for patients whose disease has relapsed or failed to respond to treatment, or for whom no treatments exist.
I’ve seen promising results from clinical trials, including a recent study evaluating a one-time treatment for patients with relapsed or refractory AL amyloidosis. Yet despite these remarkable advances, I find it deeply troubling that, for patients with such a profound unmet medical need, I am still left wondering when—or even if—these promising therapies will ever become available to the patients who desperately need them.
While investigational therapies should require rigorous evaluation of their safety and effectiveness, the FDA must recognize that traditional trial requirements aren’t always feasible for rare diseases.
Patients shouldn’t have to choose between scientific rigor and timely access to new treatments. They deserve both.
The Rare Disease Framework offers an opportunity to strike that balance. If confirmed, Overton should establish clear expectations for when alternative trial designs, including single-arm studies, may support approval. The FDA must consider disease severity, existing treatment options, the strength of clinical responses and clinical benefit when determining what evidence is sufficient.
Just as importantly, the FDA must communicate those expectations early. Researchers cannot efficiently develop new treatments when the standards they are expected to meet remain uncertain.
Patients and physicians deserve a voice in these decisions. Those of us treating rare diseases understand how quickly patients can deteriorate, where existing therapies fall short and what meaningful improvement looks like. Initiatives like the Amyloidosis Forum, a partnership between the FDA and the Amyloidosis Research Consortium, demonstrate the value of bringing regulators, researchers and other stakeholders together to address these challenges. These perspectives should also help inform regulatory decisions alongside clinical evidence.
The FDA has recognized the need for change. Now it must follow through with clear, predictable approval pathways that reflect the realities of rare diseases.
The stakes couldn’t be higher for rare disease patients. I cannot stop their disease from progressing while they wait for new options. But the FDA can help ensure promising treatments aren’t delayed by unnecessary regulatory uncertainty and barriers that continue to challenge drug development in rare diseases.
Heather J. Landau, MD, is Director of the Amyloidosis Program and a bone marrow transplant and cellular therapy specialist at Memorial Sloan Kettering Cancer Center in New York. A board-certified hematologist and oncologist, she specializes in treating AL amyloidosis and other plasma cell disorders, with a research focus on developing innovative therapies to improve patient outcomes. She has authored more than 100 peer-reviewed publications.